MEDI-3726

N/A

Report date: 2024/09/30 20:00:32

Base Information

Drug NameMEDI-3726
Drug Alias NameMEDI-3726ADCT-401
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA cross linking agents
TargetsDNA
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmuneAdc Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A